Cullinan Therapeutics (CGEM) Net Income towards Common Stockholders: 2020-2024
Historic Net Income towards Common Stockholders for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$167.6 million.
- Cullinan Therapeutics' Net Income towards Common Stockholders rose 5.56% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 241.97%. This contributed to the annual value of -$167.6 million for FY2024, which is 8.04% down from last year.
- According to the latest figures from FY2024, Cullinan Therapeutics' Net Income towards Common Stockholders is -$167.6 million, which was down 8.04% from -$155.1 million recorded in FY2023.
- Cullinan Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $109.2 million during FY2022, with a 5-year trough of -$167.6 million in FY2024.
- Its 3-year average for Net Income towards Common Stockholders is -$71.2 million, with a median of -$155.1 million in 2023.
- Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 261.81% in 2022, then plummeted by 242.04% in 2023.
- Over the past 5 years, Cullinan Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$59.4 million in 2020, then fell by 13.52% to -$67.5 million in 2021, then soared by 261.81% to $109.2 million in 2022, then tumbled by 242.04% to -$155.1 million in 2023, then fell by 8.04% to -$167.6 million in 2024.